公司資料
Tenax Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- TENX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.75 USD (-1.69%)
收盤價
最後更新: 2026年8月21日
290M USD
市值
股價為何變動
As of Aug 21, 2026, TENX closed down 1.69% at $1.75. No new same-company headline was identified in the current news window.
公司概覽
Phase 3 Cardiopulmonary Developer
Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary disease. Its strategy is centered on levosimendan, a K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF.
Lead Program: TNX-103
TNX-103 is the oral formulation of levosimendan and is being evaluated in two pivotal Phase 3 trials, LEVEL and LEVEL-2. The program is designed for a disease setting with no approved therapy, giving Tenax a focused development path in a high-need cardiopulmonary population.
Clinical Rationale
Levosimendan has prior global experience as an intravenous therapy for acutely decompensated heart failure outside the U.S. and Canada. Tenax's Phase 2 HELP trial and open-label extension supported the potential for IV TNX-101 and oral TNX-103 to improve exercise capacity, quality of life, and other clinical assessments in PH-HFpEF.
Strategic Position
Tenax is best understood as a single-asset, late-stage cardiopulmonary company. Its value is tightly linked to whether oral levosimendan can establish clinically meaningful benefit in PH-HFpEF and support a regulatory path in a market with no approved product.
未來催化劑
- Topline data from the Phase 3 LEVEL trial expected in August 2026.
- LEVEL results presentation planned for ESC Congress 2026.
- Expected LEVEL-2 enrollment completion by the end of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。